| 摘要 |
The present invention concerns the use of at least one p75NTR receptor inhibitor, alone or in association with at least one TrkA receptor activator, or at least one TrkA receptor activator, for the treatment of chronic inflammatory diseases as, for example, rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, multiple sclerosis, intestinal chronic inflammatory diseases, Lupus Erythematosus. |
